Limaye, Meghana A
Brubaker, Sara
Randis, Tara M
Ratner, Adam J
Article History
Received: 12 November 2022
Accepted: 8 May 2023
First Online: 19 May 2023
Declarations
:
: The original study was approved by the Institutional Review Boards at Columbia and Cornell, and the current study was approved by the Institutional Review Board at NYU (i16-00780), approved 8/24/16. All methods were performed in accordance with the relevant guidelines and regulations.
: Not applicable.
: AJR has served as a consultant for Pfizer and on a compassionate use advisory board for CompAC (NYU/Janssen), both outside the scope of this manuscript. All other authors report no conflicts of interest.